23 October 2018

AstraZeneca and Innate Pharma enter into partnership for the development of CD39 mAbs
23 October 2018

On October 23, 2018, Innate Pharma announced that it had entered into a development collaboration and option for further co-development and co-commercialisation with AstraZeneca for its CD39 monoclonal antibody, IPH5201.
[ Read more ]
17 June 2018

Meet us at the 2018 Bio Convention to be held in Boston
17 June 2018

Jeremy Bastid, Chief Operating Officer, will attend the 2018 BIO International Convention, to be held in Boston, Massachusetts, June 4-7, 2018.
[ Read more ]
27 April 2017

IL-17B program to be presented at AACR 2017
27 April 2017

OREGA will present latest in vivo data of its IL-17B program at the upcoming AACR annual conference to be held in Washington DC. SESSION PO.IM02.06 – Cytokines: The First Modern Immunotherapies April 3, 2017, 8:00 AM – 12:00 PM 1602 / 10 – Generation of anti-IL-17B antibodies neutralizing IL-17B-mediated alterations of the immune microenvironment, promotion of tumor cell initiating capacity and chemoresistance
[ Read more ]
27 March 2017

PRESS RELEASE – IL-17 patent to be granted in the US
27 March 2017

Press Release Lyon, France, April 18, 2017 –  OREGA Biotech, the biotech company committed to the development of novel monoclonal antibody-based immunotherapy for cancer patients, announced today that it has received a notification of allowance from the USPTO stating its intention to grant a patent application filed by OREGA Biotech and related to novel anti-IL-17 antibodies. This patent covers antibodies binding to a functional epitope of IL-17 identified by OREGA Biotech and protects several specific neutralizing antibodies able to bind and inhibit IL-17 homodimer and heterodimer. Based on the date of the priority data, the expected expiration date of this patent is at least until 2032. The related European Patent has already been granted in 2016. “The delivery of this US Patent is a significant milestone for OREGA Biotech’s IL-17 program. Our business model relies on our ability to discover novel targets and to generate IP rights over targets or broad claims such as functional epitopes”, commented Jeremy Bastid, Chief Operating Officer of OREGA Biotech.  As of today, the patent portfolio of the company is composed of 9 families of patent applications owned or co-owned by OREGA biotech. Read the press release.
[ Read more ]